A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

Name: A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Published: 2019
License: Public Domain

Kymab Limited · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

cervical-cancer gastric-cancer hepatocellular-carcinoma melanoma non-small-cell-lung-cancer pancreatic-cancer renal-cell-carcinoma triple-negative-breast-cancer

squamous cell carcinoma of head and neck, non-small cell lung cancer, hepatocellular carcinoma, esophageal cancer, gastric cancer, melanoma, renal cell carcinoma, pancreatic cancer, cervical cancer, triple negative breast cancer, advanced cancer, metastatic cancer

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 830569
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.